Logo image of ANRO

ALTO NEUROSCIENCE INC (ANRO) Stock Fundamental Analysis

NYSE:ANRO - New York Stock Exchange, Inc. - US02157Q1094 - Common Stock - Currency: USD

2.45  -0.04 (-1.61%)

After market: 2.46 +0.01 (+0.41%)

Fundamental Rating

2

ANRO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. ANRO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ANRO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ANRO has reported negative net income.
ANRO had a negative operating cash flow in the past year.
ANRO Yearly Net Income VS EBIT VS OCF VS FCFANRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

The Return On Assets of ANRO (-34.60%) is comparable to the rest of the industry.
ANRO has a Return On Equity (-40.56%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -34.6%
ROE -40.56%
ROIC N/A
ROA(3y)-43.67%
ROA(5y)N/A
ROE(3y)-58.16%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ANRO Yearly ROA, ROE, ROICANRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

ANRO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANRO Yearly Profit, Operating, Gross MarginsANRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 -1K -2K -3K -4K -5K

More info and screens

5

2. Health

2.1 Basic Checks

Compared to 1 year ago, ANRO has more shares outstanding
ANRO has a better debt/assets ratio than last year.
ANRO Yearly Shares OutstandingANRO Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M 15M 20M 25M
ANRO Yearly Total Debt VS Total AssetsANRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of 0.24, we must say that ANRO is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of ANRO (0.24) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.08 indicates that ANRO is not too dependend on debt financing.
The Debt to Equity ratio of ANRO (0.08) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z 0.24
ROIC/WACCN/A
WACCN/A
ANRO Yearly LT Debt VS Equity VS FCFANRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 16.92 indicates that ANRO has no problem at all paying its short term obligations.
With an excellent Current ratio value of 16.92, ANRO belongs to the best of the industry, outperforming 89.39% of the companies in the same industry.
A Quick Ratio of 16.92 indicates that ANRO has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 16.92, ANRO belongs to the top of the industry, outperforming 89.39% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 16.92
Quick Ratio 16.92
ANRO Yearly Current Assets VS Current LiabilitesANRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M 150M

More info and screens

0

3. Growth

3.1 Past

ANRO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -75.89%.
EPS 1Y (TTM)-75.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.79%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ANRO is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -7.48% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-7.11%
EPS Next 2Y-10.2%
EPS Next 3Y-7.48%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANRO Yearly Revenue VS EstimatesANRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 50K 100K 150K 200K
ANRO Yearly EPS VS EstimatesANRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ANRO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ANRO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANRO Price Earnings VS Forward Price EarningsANRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANRO Per share dataANRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

ANRO's earnings are expected to decrease with -7.48% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-10.2%
EPS Next 3Y-7.48%

More info and screens

0

5. Dividend

5.1 Amount

ANRO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALTO NEUROSCIENCE INC

NYSE:ANRO (5/1/2025, 8:45:08 PM)

After market: 2.46 +0.01 (+0.41%)

2.45

-0.04 (-1.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-20 2025-03-20/amc
Earnings (Next)N/A N/A
Inst Owners88.31%
Inst Owner Change0.01%
Ins Owners7.51%
Ins Owner Change0%
Market Cap66.32M
Analysts86.15
Price Target11.73 (378.78%)
Short Float %13.18%
Short Ratio9.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.25%
Min EPS beat(2)6.96%
Max EPS beat(2)15.54%
EPS beat(4)3
Avg EPS beat(4)-6.64%
Min EPS beat(4)-61.28%
Max EPS beat(4)15.54%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.54%
PT rev (3m)-2.54%
EPS NQ rev (1m)4.15%
EPS NQ rev (3m)3.8%
EPS NY rev (1m)-0.11%
EPS NY rev (3m)-5.3%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.44
P/tB 0.44
EV/EBITDA N/A
EPS(TTM)-2.54
EYN/A
EPS(NY)-2.72
Fwd EYN/A
FCF(TTM)-1.83
FCFYN/A
OCF(TTM)-1.75
OCFYN/A
SpS0
BVpS5.6
TBVpS5.6
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.6%
ROE -40.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.67%
ROA(5y)N/A
ROE(3y)-58.16%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 413.35%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.92
Quick Ratio 16.92
Altman-Z 0.24
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)251.13%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-75.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.79%
EPS Next Y-7.11%
EPS Next 2Y-10.2%
EPS Next 3Y-7.48%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-81.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-15.77%
EBIT Next 3Y-23.96%
EBIT Next 5YN/A
FCF growth 1Y-45.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-41.78%
OCF growth 3YN/A
OCF growth 5YN/A